FDA
-
-
-
-
-
-
-
Novartis opens radioligand therapy manufacturing facility in California
-
-
-
-
-
-
-
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
-
-
-
-
-
-
-
US appeals court reinstates pause on generic version of Novartis' Entresto
-
-
-
-
-
-
-
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
-
-
-
-
-
-
-
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
-
-
-
-
-
-
-
Novartis (NVS) Expands Production of Pluvicto
-
322,882 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

